MX2020003862A - Derivados condensados de imidazol sustituidos por grupos hidroxi terciarios como inhibidores de fosfoinositido 3-cinasas gamma (pi3k-gamma). - Google Patents

Derivados condensados de imidazol sustituidos por grupos hidroxi terciarios como inhibidores de fosfoinositido 3-cinasas gamma (pi3k-gamma).

Info

Publication number
MX2020003862A
MX2020003862A MX2020003862A MX2020003862A MX2020003862A MX 2020003862 A MX2020003862 A MX 2020003862A MX 2020003862 A MX2020003862 A MX 2020003862A MX 2020003862 A MX2020003862 A MX 2020003862A MX 2020003862 A MX2020003862 A MX 2020003862A
Authority
MX
Mexico
Prior art keywords
pi3k
hydroxy groups
imidazole derivatives
derivatives substituted
gamma inhibitors
Prior art date
Application number
MX2020003862A
Other languages
English (en)
Inventor
Lixin Shao
David M Burns
Andrew P Combs
Eddy W Yue
Richard B Sparks
Brent Douty
Stacey Shepard
Nikoo Falahatpisheh
Andrew W Buesking
Jalluri Ravi Kumar
Daniel Levy
Padmaja Polam
Artem Shvartsbart
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of MX2020003862A publication Critical patent/MX2020003862A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de Fórmula (I):o sales de los mismos farmacéuticamente aceptables, los cuales son inhibidores de PI3K-? los cuales son útiles para el tratamiento de trastornos tales como enfermedades autoinmunes, cáncer, enfermedades cardiovasculares, y enfermedades neurodegenerativas.
MX2020003862A 2017-10-18 2018-10-17 Derivados condensados de imidazol sustituidos por grupos hidroxi terciarios como inhibidores de fosfoinositido 3-cinasas gamma (pi3k-gamma). MX2020003862A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762574057P 2017-10-18 2017-10-18
US201762608897P 2017-12-21 2017-12-21
US201862727316P 2018-09-05 2018-09-05
PCT/US2018/056311 WO2019079469A1 (en) 2017-10-18 2018-10-17 CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED WITH HYDROXY TERTIARY GROUPS AS INHIBITORS OF PI3K-GAMMA

Publications (1)

Publication Number Publication Date
MX2020003862A true MX2020003862A (es) 2020-08-13

Family

ID=64110207

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003862A MX2020003862A (es) 2017-10-18 2018-10-17 Derivados condensados de imidazol sustituidos por grupos hidroxi terciarios como inhibidores de fosfoinositido 3-cinasas gamma (pi3k-gamma).

Country Status (33)

Country Link
US (4) US10738057B2 (es)
EP (2) EP4006034A1 (es)
JP (2) JP7244504B2 (es)
CN (2) CN111542526B (es)
AU (2) AU2018350980B2 (es)
BR (1) BR112020007593A2 (es)
CA (1) CA3084589A1 (es)
CL (1) CL2020001047A1 (es)
CR (2) CR20200214A (es)
CY (1) CY1124814T1 (es)
EC (1) ECSP20024651A (es)
ES (1) ES2902390T3 (es)
GE (1) GEP20237483B (es)
HR (1) HRP20211827T1 (es)
HU (1) HUE056615T2 (es)
IL (3) IL295978B1 (es)
JO (1) JOP20200086A1 (es)
LT (1) LT3697789T (es)
MA (1) MA50398B1 (es)
MD (1) MD3697789T2 (es)
MX (1) MX2020003862A (es)
PE (1) PE20210169A1 (es)
PH (1) PH12020550442A1 (es)
PL (1) PL3697789T3 (es)
PT (1) PT3697789T (es)
RS (1) RS62818B1 (es)
SA (1) SA520411783B1 (es)
SG (1) SG11202003428VA (es)
SI (1) SI3697789T1 (es)
TW (2) TWI803525B (es)
UA (1) UA128085C2 (es)
WO (1) WO2019079469A1 (es)
ZA (1) ZA202201220B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3697789T1 (sl) 2017-10-18 2022-04-29 Incyte Corporation Kondenzirani imidazolni derivati, substituirani s terciarnimi hidroksi skupinami, kot zaviralci PI3K-gama
PT3728271T (pt) 2017-12-19 2022-10-06 Turning Point Therapeutics Inc Compostos macrocíclicos para tratar doenças
CR20240101A (es) 2018-03-08 2024-05-24 Incyte Corp COMPUESTOS DIÓLICOS DE AMINOPIRAZINA COMO INHIBIDORES DE PI3K-y (DIVISIONAL 2020-464)
US11161850B2 (en) 2018-07-05 2021-11-02 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
RS65334B1 (sr) 2018-09-05 2024-04-30 Incyte Corp Kristalni oblici inhibitora fosfatidilinozitol 3-kinaze (pi3k)
CN115286521B (zh) * 2022-07-11 2023-11-03 上海医药集团(本溪)北方药业有限公司 一种盐酸左沙丁胺醇的合成方法

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4269846A (en) 1979-10-29 1981-05-26 Usv Pharmaceutical Corporation Heterocyclic compounds useful as anti-allergy agents
US5137876A (en) 1990-10-12 1992-08-11 Merck & Co., Inc. Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
JP4516690B2 (ja) 1998-08-11 2010-08-04 ノバルティス アーゲー 血管形成阻害活性を有するイソキノリン誘導体
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0011092D0 (en) 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (III)
EP1294358B1 (en) 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process
AU2002337142B2 (en) 2001-09-19 2007-10-11 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
JP5039268B2 (ja) 2001-10-26 2012-10-03 アベンティス・ファーマスーティカルズ・インコーポレイテツド ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用
FR2831536A1 (fr) 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
DK1441737T3 (da) 2001-10-30 2006-11-13 Novartis Ag Staurosporin-derivater som inhibitorer af FLT3-receptor-tyrosinkinase-aktivitet
DE10207843A1 (de) 2002-02-15 2003-09-04 Schering Ag Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
CL2003002353A1 (es) 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7157460B2 (en) 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7186832B2 (en) 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
WO2004078943A2 (en) 2003-03-04 2004-09-16 California Institute Of Technology Alternative heterocycles for dna recognition
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
CA2534649A1 (en) 2003-08-01 2005-02-10 Genelabs Technologies, Inc. Bicyclic imidazol derivatives against flaviviridae
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
RU2405784C2 (ru) * 2003-10-15 2010-12-10 Оси Фармасьютикалз, Инк. Имидазопиразины в качестве ингибиторов тирозинкиназ
WO2005118580A2 (en) 2004-05-12 2005-12-15 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Tricyclic compounds as inhibitors of the hypoxic signaling pathway
MXPA06014247A (es) 2004-06-10 2007-03-12 Irm Llc Compuestos y composiciones como inhibidores de la proteina quinasa.
RU2007123675A (ru) 2004-11-24 2008-12-27 Новартис АГ (CH) Комбинации ингибиторов jak
US20070037865A1 (en) 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
JP2009507032A (ja) 2005-09-02 2009-02-19 アボット・ラボラトリーズ 新規なイミダゾ系複素環
BRPI0713328A2 (pt) 2006-06-22 2012-10-30 Biovitrum Ab derivados de piridina e pirazina como inibidores de cinase mnk
WO2009005551A2 (en) 2007-03-27 2009-01-08 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
DE102007035333A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
BRPI0820544A2 (pt) 2007-11-16 2015-06-16 Incyte Corp 4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase
WO2009079011A1 (en) 2007-12-19 2009-06-25 The Scripps Research Institute Benzimidazoles and analogs as rho kinase inhibitors
CA2712071A1 (en) 2008-01-15 2009-10-08 Siga Technologies, Inc. Antiviral drugs for treatment of arenavirus infection
ATE555116T1 (de) 2008-02-26 2012-05-15 Merck Sharp & Dohme Ahcy-hydrolasehemmer zur behandlung von hyperhomocysteinämie
BRPI0909040B8 (pt) 2008-03-11 2021-05-25 Incyte Holdings Corp derivados de azetidina e ciclobutano, seus usos, e composição
WO2009133127A1 (en) 2008-04-30 2009-11-05 Merck Serono S.A. Fused bicyclic compounds and use thereof as pi3k inhibitors
WO2009158118A2 (en) 2008-05-30 2009-12-30 University Of Notre Dame Du Lac Anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria
US8470819B2 (en) 2008-11-03 2013-06-25 Merck Sharp & Dohme Corp. Benzimidazole and aza-benzimidazole carboxamides
WO2010061903A1 (ja) 2008-11-27 2010-06-03 塩野義製薬株式会社 Pi3k阻害活性を有するピリミジン誘導体およびピリジン誘導体
GB0822981D0 (en) 2008-12-17 2009-01-21 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
CA2753560A1 (en) 2009-02-27 2010-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of phosphatidylinositol 3-kinase
WO2010119264A1 (en) * 2009-04-16 2010-10-21 Centro Nacional De Investigaciones Oncólogicas (Cnio) Imidazopyrazines for use as kinase inhibitors
US8716303B2 (en) 2009-05-22 2014-05-06 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
RS53494B9 (sr) 2009-06-29 2020-11-30 Incyte Holdings Corp Pirimidinoni kao inhibitori pi3k
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2011075630A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
WO2011099832A2 (en) 2010-02-12 2011-08-18 Crystalgenomics, Inc. Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
DK3050882T3 (en) 2010-03-10 2018-03-19 Incyte Holdings Corp PIPERIDIN-4-YL-AZETIDINE DERIVATIVES AS JAK1 INHIBITORS
JP2013523766A (ja) 2010-03-31 2013-06-17 グラクソ グループ リミテッド キナーゼ阻害剤としてのイミダゾリル‐イミダゾール
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
WO2011149856A1 (en) 2010-05-24 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
US8623857B2 (en) 2010-05-26 2014-01-07 Merck Sharp & Dohme Corp. N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
AR083450A1 (es) 2010-10-13 2013-02-27 Millennium Pharm Inc Heteroarilos y sus usos en el tratamiento de enfermedades proliferativas, inflamatorias o cardiovasculares
UA113156C2 (xx) 2010-11-19 2016-12-26 Циклобутилзаміщені похідні піролопіридину й піролопіримідину як інгібітори jak
JP5917544B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
KR20140001965A (ko) 2010-11-30 2014-01-07 다케다 야쿠힌 고교 가부시키가이샤 바이시클릭 화합물
AR084366A1 (es) 2010-12-20 2013-05-08 Incyte Corp N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US8673905B2 (en) 2011-03-17 2014-03-18 Hoffmann-La Roche Inc. Imidazo pyrazines
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
US9029389B2 (en) 2011-04-21 2015-05-12 Institut Pasteur Korea Anti-inflammation compounds
JP6463631B2 (ja) 2011-06-09 2019-02-06 ライゼン・ファーマシューティカルズ・エスアー Ｇｐｒ−１１９のモジュレータとしての新規化合物
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
HUE043703T2 (hu) 2011-09-02 2019-09-30 Incyte Holdings Corp Heterociklusos aminok PI3K inhibitorokként
WO2013104610A1 (en) * 2012-01-10 2013-07-18 Bayer Intellectual Property Gmbh Substituted imidazopyrazines as akt kinase inhibitors
WO2013129674A1 (ja) 2012-03-01 2013-09-06 学校法人兵庫医科大学 新規ベンズイミダゾール誘導体及びその用途
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
CN104334552B (zh) 2012-05-31 2016-08-31 住友化学株式会社 稠合杂环化合物
JP6259823B2 (ja) 2012-07-13 2018-01-10 ユーシービー バイオファルマ エスピーアールエル Ｔｎｆ活性の調節物質としてのイミダゾピリジン誘導体
SG10201703533VA (en) 2012-11-01 2017-06-29 Incyte Corp Tricyclic fused thiophene derivatives as jak inhibitors
TWI736135B (zh) 2013-03-01 2021-08-11 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
US8999992B2 (en) 2013-03-15 2015-04-07 Vm Pharma Llc Crystalline forms of tryosine kinase inhibitors and their salts
WO2014149207A2 (en) 2013-03-15 2014-09-25 Dow Agrosciences Llc Benzimidazole-based insecticidal compositions and related methods
EP2976077A4 (en) 2013-03-22 2016-11-30 Scripps Research Inst BENZIMIDAZOLES SUBSTITUTED AS MODULATORS OF A NOCICEPTIN RECEPTOR
EP2994142A4 (en) 2013-05-08 2017-03-29 Colorado Seminary, Which Owns and Operates The University of Denver Antibiotic and anti-parasitic agents that modulate class ii fructose 1,6-bisphosphate aldolase
EP4275756A3 (en) 2013-05-17 2024-02-07 Incyte Holdings Corporation Bipyrazole derivatives as jak inhibitors
CA2917267C (en) 2013-07-17 2021-12-28 Otsuka Pharmaceutical Co., Ltd. Cyanotriazole compounds
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MA54622A (fr) 2014-04-08 2021-11-03 Incyte Corp Traitement d'affections malignes par lymphocytes b par un inhibiteur jak et pi3k combiné
EP2930048A1 (en) 2014-04-10 2015-10-14 Johnson Controls Automotive Electronics SAS Head up display projecting visual information onto a screen
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
CA2961525A1 (en) 2014-09-16 2016-03-24 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US10214537B2 (en) * 2014-10-22 2019-02-26 Bristol-Myers Squibb Company Bicyclic heteroaryl amine compounds
ES2749679T3 (es) * 2014-10-22 2020-03-23 Bristol Myers Squibb Co Compuestos de pirrolotriazina amina sustituidos como inhibidores de PI3k
MA40933A (fr) 2014-11-11 2017-09-19 Piqur Therapeutics Ag Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
WO2016106624A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Tertiary alcohol imidazopyrazine btk inhibitors
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
US9968604B2 (en) * 2015-04-16 2018-05-15 Chiesi Farmaceutici S.P.A. Chromene derivatives as phoshoinositide 3-kinases inhibitors
WO2016183094A1 (en) 2015-05-12 2016-11-17 Kalyra Pharmaceuticals, Inc. Bicyclic compounds
HUE059324T2 (hu) 2015-11-06 2022-11-28 Incyte Corp Heterociklusos vegyületek, mint PI3K-gamma inhibitorok
AR107293A1 (es) 2016-01-05 2018-04-18 Incyte Corp COMPUESTOS DE PIRIDINA Y PIRIDIMINA COMO INHIBIDORES DE PI3K-g
TW201803871A (zh) 2016-06-24 2018-02-01 英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物
BR112019003710A2 (pt) 2016-08-26 2019-05-28 Mitsubishi Tanabe Pharma Corp inibidor de pde7, composto, composição farmacêutica, uso de um inibidor de pde7 ou de um composto, e, método para tratar ou prevenir uma doença que é melhorada pela inibição de pde7.
WO2018136754A1 (en) 2017-01-20 2018-07-26 Massachusetts Institute Of Technology Injectable polymer micro-depots for controlled local drug delivery
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
MX2020000911A (es) 2017-07-24 2020-09-10 Novartis Ag Star Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp.
US10988454B2 (en) 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
EP3697762A4 (en) 2017-10-18 2021-04-07 Epizyme, Inc. AMINE SUBSTITUTED HETEROCYCLIC COMPOUNDS, USED AS EHMT2 INHIBITORS, SALTS THEREOF, AND THEIR METHODS OF SYNTHESIS
SI3697789T1 (sl) 2017-10-18 2022-04-29 Incyte Corporation Kondenzirani imidazolni derivati, substituirani s terciarnimi hidroksi skupinami, kot zaviralci PI3K-gama
PT3728271T (pt) 2017-12-19 2022-10-06 Turning Point Therapeutics Inc Compostos macrocíclicos para tratar doenças
US11512054B2 (en) 2017-12-21 2022-11-29 Basf Se Pesticidal compounds
CN111372932B (zh) 2017-12-21 2023-11-21 勃林格殷格翰国际有限公司 作为sos1抑制剂的新颖苄氨基取代吡啶并嘧啶酮及衍生物
RS65334B1 (sr) 2018-09-05 2024-04-30 Incyte Corp Kristalni oblici inhibitora fosfatidilinozitol 3-kinaze (pi3k)

Also Published As

Publication number Publication date
JP7541594B2 (ja) 2024-08-28
TWI803525B (zh) 2023-06-01
KR20200089264A (ko) 2020-07-24
SI3697789T1 (sl) 2022-04-29
US20220213107A1 (en) 2022-07-07
US20190152975A1 (en) 2019-05-23
JP2023085290A (ja) 2023-06-20
MA50398A (fr) 2021-05-05
BR112020007593A2 (pt) 2020-09-24
JP7244504B2 (ja) 2023-03-22
CA3084589A1 (en) 2019-04-25
WO2019079469A1 (en) 2019-04-25
SG11202003428VA (en) 2020-05-28
PT3697789T (pt) 2021-12-31
CN111542526B (zh) 2024-01-09
IL295978A (en) 2022-10-01
CR20210442A (es) 2021-12-20
IL295978B1 (en) 2023-09-01
EP4006034A1 (en) 2022-06-01
US20200385392A1 (en) 2020-12-10
AU2023203088B2 (en) 2024-10-03
HUE056615T2 (hu) 2022-02-28
GEP20237483B (en) 2023-03-27
US20240228498A1 (en) 2024-07-11
CR20200214A (es) 2020-07-25
JOP20200086A1 (ar) 2020-04-30
TW201927788A (zh) 2019-07-16
PE20210169A1 (es) 2021-01-29
TW202340200A (zh) 2023-10-16
ES2902390T3 (es) 2022-03-28
IL295978B2 (en) 2024-01-01
HRP20211827T1 (hr) 2022-03-18
IL273983A (en) 2020-05-31
EP3697789B1 (en) 2021-09-29
CY1124814T1 (el) 2022-11-25
RS62818B1 (sr) 2022-02-28
AU2018350980B2 (en) 2023-02-23
IL273983B2 (en) 2023-02-01
AU2018350980A1 (en) 2020-04-30
US11926630B2 (en) 2024-03-12
TWI834560B (zh) 2024-03-01
MA50398B1 (fr) 2021-10-29
US11225486B2 (en) 2022-01-18
CL2020001047A1 (es) 2020-08-28
EP3697789A1 (en) 2020-08-26
ECSP20024651A (es) 2020-06-30
PH12020550442A1 (en) 2021-05-31
SA520411783B1 (ar) 2024-05-12
US10738057B2 (en) 2020-08-11
IL273983B (en) 2022-10-01
ZA202201220B (en) 2023-03-29
LT3697789T (lt) 2021-12-10
CN111542526A (zh) 2020-08-14
AU2023203088A1 (en) 2023-06-15
MD3697789T2 (ro) 2022-02-28
JP2021500340A (ja) 2021-01-07
UA128085C2 (uk) 2024-04-03
CN118063470A (zh) 2024-05-24
PL3697789T3 (pl) 2022-02-21

Similar Documents

Publication Publication Date Title
ECSP24026455A (es) Compuestos de pirrolotriazina como inhibidores de tam
MX2020003862A (es) Derivados condensados de imidazol sustituidos por grupos hidroxi terciarios como inhibidores de fosfoinositido 3-cinasas gamma (pi3k-gamma).
ECSP17073191A (es) Compuestos heterocíclicos como inhibidores de lsd1
ECSP20060827A (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
CY1123059T1 (el) Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1
CO2017011484A2 (es) Inhibidores de bromodominio
DOP2016000299A (es) Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1
CL2017000712A1 (es) Pirimidinonas como inhibidores del factor xia
DOP2015000158A (es) Inhibidores de prmt5 y sus usos
ECSP16073190A (es) Ciclopropilaminas como inhibidores de lsd1
ECSP17006821A (es) Inhibidores de la desmetilasa-1 específica de la lisina
CY1124243T1 (el) Αναστολη του ιοντικου διαυλου υποδοχεα παροδικου δυναμικου α1
ECSP20061378A (es) COMPUESTOS DIÓLICOS DE AMINOPIRAZINA COMO INHIBIDORES DE PI3K-gamma
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
ECSP17006776A (es) Inhibidores de la desmetilasa-1 específica de la lisina
CO7280468A2 (es) Antagonistas del receptor de 5-ht3
BR112016024936A2 (pt) moduladores de gpr40 à base de pirrolidina para tratamento de doenças como diabetes
CO2017000011A2 (es) Derivados de quinolizinona como inhibidores de pi3k
NI201801172A (es) Nuevos compuestos para el tratamiento de enfermedades parasitarias
UY36758A (es) Inhibidores del potenciador del homólogo zeste 2
EA201792109A1 (ru) Конденсированные с тетрагидрофураном производные аминогидротиазина, пригодные для лечения болезни альцгеймера
EA201892188A1 (ru) Соединения пирролотриазина в качестве ингибиторов tam
CR20160532A (es) Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1